

ANNUAL REPORT

Accelerating Diagnosis, Treatments, and a **Cure** for Celiac Disease













celiac.org

ACCFI FRATING RESEARCH

Strategic investments in cutting-edge biomedical research and patient engagement to advance the pursuit of treatments and a cure for celiac disease.

PROMOTING **EDUCATION**

Outreach to patients and healthcare providers has improved the diagnostic rate of celiac disease. Focused investments continue to close the gap and end the needless suffering of millions.

EFFECTIVE **ADVOCACY**

Committed to being the worldwide voice of the celiac community Congress and federal research and

Driving Innovation -

Presentation by CEO Marilyn Geller on patient unmet needs at **NIAID Accelerating Progress in Celiac Disease Workshop** to secure NIH funding for celiac disease research.

Trained Patient Advocates to present at the FDA's **Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI** (GREAT VI) Workshop on Celiac Disease to inform clinical trial endpoints for celiac disease drug development.

Recruited for **Boston Children's Hospital's** study evaluating access to gluten-free food to inform federal policy changes for low-income food assistance.

Impacting Patients -



6.5M **VISITORS TO CELIAC.ORG** annually

Providing Support to the CELIAC DISEASE COMMUNITY Through **SOCIAL MEDIA OUTREACH**

3.3M **REACHED** in 2021





3,000 **COMMUNITY FUNDRAISING PARTICIPANTS** in 2021

Expanding Reach in 2021

Convened the 2021 Patient Education & Advocacy Summit, supported by a **PCORI Engagement Award,** resulting in more than 420 advocates trained to effectively advocate to their Members of Congress, in addition to more than 120 advocates trained through iadvocate.celiac.org.

Partnered with Congresswoman McCollum to introduce the first ever Congressional Celiac Disease Caucus to support innovative celiac disease research and advance legislation to ease the suffering of celiac disease patients.

Secured FY2021 federal budget report language directing NIH to study celiac disease for the second consecutive year.

Advancing Therapeutic Treatment Development



Probiotic Use in Celiac Disease: Results from a National Survey published August 2021 in



the Journal of Gastrointestinal and Liver Diseases using data from iCureCeliac®. icure.celiac.org



iqualify.celiac.org

First time simultaneously recruiting for clinical trials in three different phases: the ACeD Study

TRIALS & STUDIES (phase 1), PROACTIVE Celiac Study (phase 2b), and CeDLara Study (phase 3). supported



Funded four Research Grant Awards in developing less allergenic wheat, determining whether blocking B cells can reduce intestinal

\$1,300,000 2018 - 2021 **FUNDING OF RESEARCH** & MEDICAL EDUCATION

damage, mortality rates for celiac disease patients and risk of psychiatric disorders, and evaluation of a diagnostic test that requires only a single dose of gluten.

Educating Providers and the Public -

NASPGHAN Clinical Guide for Pediatric Celiac Disease web-based tool to assist healthcare professionals in the diagnosis and management of celiac disease patients, improving the quality and effectiveness of care provided. clinical.celiac.org



Certificate of Training in Treating Gluten-Related Disorders developed by the Academy of Nutrition and Dietetics with the support of the Celiac Disease Foundation and reimbursement grants offered to increase the pool of registered dietitians skilled in celiac disease nutritional therapy.



Celiac Disease Management for Learning Environments Training Program web-based instruction for schools, parents, and caregivers on implementation of standardized accommodations required by the Americans with Disabilities Act, based upon what is medically and psychologically necessary for children with celiac disease to succeed at school.



Driving Policy Change —

school.celiac.ora

Launched a campaign to support the reintroduction of the **Medical Nutrition Therapy Act of 2021**, bipartisan legislation to provide coverage of nutrition therapy to Medicare beneficiaries.

Partnered in a multi-organization campaign in support of the **Food Labeling Modernization Act of 2021** to update front-of-package food labeling requirements to make it easier and safer for individuals with celiac disease to purchase food items by disclosing when foods contain gluten.

Coordinated with Congressman Ryan's office to launch a campaign supporting the reintroduction of the Gluten in Medicine Disclosure Act of **2021** to make it easier for consumers to identify gluten in prescription drugs.



540 STATE ADVOCACY **AMBASSADORS** trained



9,785 **SENT TO CONGRESS** since November 2020



2020 FINANCIALS

ASSETS

Cash and Cash Equivalents	\$ 2,378,171
Contributions Receivable	\$ 177,043
Accounts Receivable	\$ 160,500
Investment in Partnership	\$ 89,268
Deposits	\$ 3,250
Property and Equipment	\$ 128,301

Total Assets	\$ 2,936,533
104417133613	T =/// 00/000

LIABILITIES

Accounts Payable	\$ 32,942
Accrued Salaries	\$ 52,814
Unearned Revenue	\$ 179,084
Loan Payable -	\$ 130,800
Payroll Protection Program	
Grants Payable	\$ 361,650

Tabal	Liabilities	\$757,290
	i i labilities	5/5/-/90

NET ASSETS

Unrestricted \$ 2,179,243

Total Liabilities and Net Assets \$2,936,533

SUPPORT AND REVENUE

Contributions and Grants	\$ 1,093,597
Annual Meeting	\$ 9,173
Gifts in Kind	\$ 354,373
Sponsorships, Program Income,	\$ 778,175
and Special Events	

Total Revenue	\$2,235,318
iotai nevellue	3 4,433,310

EXPENSES

Program Expenses	\$ 1,569,409
Management and General	\$ 73,021
Fundraising	\$ 100,679

Total Expenses	\$1,743,109
Change in Net Assets	\$ 492,209